

Please type a plus sign (+) inside this box

CH-09-07

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing).

Total Number of Pages in This Submission

Application Number	10/619,754
Filing Date	July 14, 2003
First Named Inventor	Bossenmaier, B.
Group/Art Unit	1643
Examiner Name	Holleran, Anne L.

39766-0114

ENCLOSURES (check all that apply)

- Fee Transmittal Form
 - Fee Attached
- Amendment / Response
 - After Final
 - Version With Markings Showing Changes
 - Affidavits/declaration(s)
- Extension of Time Request
- Information Disclosure Statement w/13 References
- Certified Copy of Priority Document(s)
- Response to Missing Parts/ Incomplete Application
 - Response to Missing Parts under 37 CFR 1.52 or 1.53
- Copy of Notice

- Recordation Cover Sheet with Executed Assignment
- Drawing(s)
- Licensing-related Papers
- Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- Petition to Convert to a Provisional Application
- Power of Attorney, by Assignee to Exclusion of Inventor Under 37 C.F.R. §3.71 With Revocation of Prior Powers
- Terminal Disclaimer
- Small Entity Statement
- Request for Refund

- After Allowance Communication to Group
- Appeal Communication to Board of Appeals and Interferences
- Proprietary Information
- Status Letter
- ADDITIONAL ENCLOSURE(S)
(PLEASE IDENTIFY BELOW):

COPY OF EP SEARCH REPORT AND RETURN POSTCARD

Remarks

AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER, REFERENCING ATTORNEY'S DOCKET NO. 39766-0114

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	HELLER EHRMAN LLP 275 Middlefield Road, Menlo Park, California 94025	GINGER R. DREGER (Reg. No. 33,055)
		Telephone: (650) 324-7000
		Facsimile: (650) 324-0638

Signature

Date

April 5, 2007

Customer Number:

25213

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: MAIL STOP xxxx, Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on this date: April 5, 2007.

Express Mail Label EV 581 478 812 US

Typed or printed name

Elena Torres


Signature


Date

April 5, 2007

Burden/Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop _____, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

4

CERTIFICATE OF EXPRESS MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA on the date indicated below.		
Express Mail Label: EV 581 478 812 US		
Typed or print name	Elena Torres 	
Signature	Date	April 5, 2007



PATENT

Attorney Docket No.: 39766-0114

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Bossenmaier, B. et al.)	Art Unit: 1643
Application No.: 10/619,754)	Examiner: Holleran, Anne L.
Filed: July 14, 2003)	
Title: METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ERB2 ANTIBODIES)	

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §1.97

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications. 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609. The references were cited in a search report for the corresponding European patent application. A copy of the search report is enclosed.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- (2) It is being filed within 3 months of entry of a national stage
-- OR --
- (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- a certification as specified in §1.97(e) is provided below; **or**
- a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No.: 39766-0114).

Respectfully submitted,

HELLER EHRLMAN LLP

By: 
GINGER R. DREGER
Reg. No.: 33,055

Dated: April 5, 2007

HELLER EHRLMAN LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: 1.650.324.7000
Facsimile: 1.650.324.0638
Customer No.: 25213

INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.	SERIAL NO.			
		39766-0114	10/619,754			
		APPLICANT: Bossenmaier, B. et al.				
		FILING DATE: 7/14/2003	GROUP: 1643			
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	2002/0064805	5/30/2002	Akita et al.			
	5,811,098	9/22/1998	Plowman et al.			
	6,417,168	7/9/2002	Greene et al.			
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
	WO 01/00245 A2	04/01/2001	PCT			<input type="checkbox"/> <input type="checkbox"/>
	WO 01/00245 A3	04/01/2001	PCT			<input type="checkbox"/> <input type="checkbox"/>
	WO 01/09186 A2	08/02/2001	PCT			<input type="checkbox"/> <input type="checkbox"/>
	WO 01/89566 A1	29/11/2001	PCT			<input type="checkbox"/> <input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Brockhoff et al., "Epidermal Growth Factor Receptor, c-erbB2 and c-erbB3 Receptor Interaction, and Related Cell Cycle Kinetics of SK-BR-3 and BT474 Breast Carcinoma Cells" Cytometry 44:338-348 (2001).					
	Chen et al., "Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3" Biochemical and Biophysical Research Communications 277:757-763 (2000).					
	Gilbertson et al., "Prognostic Significance of HER2 and HER4 Coexpression in Childhood Medulloblastoma" Cancer Research 57:3272-3280, (1997).					
	Lane et al., "ErbB2 Potentiates Breast Tumor Proliferation Through Modulation of p27 ^{Kip1} -Cdk2 Complex Formation: receptor Overexpression does not Determine Growth Dependency", Molecular and Cellular Biology, vol. 20, no. 9, pp. 3210-3223 (2000).					
	Lyne et al., "Tissue Expression of Neu Differentiation Factor/Heregulin and its Receptor Complex in Prostate cancer and its Biologic Effects on Prostate Cancer Cells in Vitro", Cancer Journal from Scientific American, vol. 3, no. 1 (1997).					
	Olayioye et al., "The ErbB Signaling Network: Receptor Heterodimerization in Development and Cancer" The EMBO Journal, vol. 19, no. 13, pp. 3159-3167 (2000).					
	Motoyama et al., "The Efficacyof ErbB reeptor-Targeted Anticancer Therapeutics is Influenced by the Availability of Epidermal Growth Factor-Related Peptides" Cancer research 62:3151-3158 (2002).					
	Neve et al., "Effects of Oncogenic ErbB2 on G1 cell Cycle Regulations in Breast Tumour Cells", Oncogene 19:1647-1656 (2000).					
	Xia et al., "Combination of EGFR, HER-2/neu, and HER-3 is a Stronger Predictor for the Outcome of Oral Squamous Cell Carcinoma than any Individual Family Members" Clinical Cancer Research vol. 5:4164-4174 (1999).					
EXAMINER		DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.